市場調查報告書
商品編碼
1403481
2030 年質子治療系統市場預測:按產品類型、類型、設定、適應症、最終用戶和地區進行的全球分析Proton Therapy Systems Market Forecasts to 2030 - Global Analysis By Product Type, Type, Set-Up, Indication, End User and By Geography |
根據 Stratistics MRC 的數據,全球質子治療系統市場在預測期內將以 15.6% 的複合年成長率成長。
質子治療系統是專為精準癌症治療而設計的先進醫療技術,可提高癌症患者的治療效果和生活品質。質子治療可以將劑量與腫瘤的形狀精確匹配,從而可以向癌細胞輸送更高的劑量,同時不傷害健康組織。
據世界衛生組織 (WHO) 稱,癌症是全球頭號死亡原因,到 2020 年將導致約 1,000 萬人死亡。
質子治療作為放射治療的一種先進型態,在癌症治療中具有多種優勢。它使用質子束精確瞄準腫瘤並提供高劑量的輻射,同時對周圍健康組織的損害最小。這種有針對性的方法降低了與傳統放射線治療相關的副作用和長期併發症的風險。質子束治療被認為是一種有價值的治療方法,因為它可以實現精確且準確的放射照射,並且市場需求不斷增加。
儘管質子治療是一種先進且有效的治療方法,但與傳統的放射治療設施相比,質子治療中心的可用性和可近性受到限制。質子治療中心的地理分佈在限制訪問方面發揮了作用。此外,由於距離遙遠且附近缺乏設施,居住在偏遠或農村地區的患者在接受質子治療時可能面臨重大挑戰。因此,缺乏准入是阻礙市場拓展的主要因素。
質子治療機設計和功能的改進與複雜的治療計劃系統相結合,使醫療保健提供者能夠提供高度針對性的放射劑量。先進成像技術的整合透過即時可視化腫瘤和周圍健康組織來提高治療精度。此外,治療計劃的軟體創新最佳化了質子治療,以滿足個別患者的需求,促進個體化和適應性的方法。因此,這些技術創新將加速市場的成長。
雖然質子治療具有獨特的優勢,但強度調控放射治療(IMRT) 和立體定位放射治療 (SBRT) 等替代技術已取得重大進展,但在某些情況下可能無法提供可比較的治療結果。調強放射治療(IMRT)是一種廣泛採用的放射治療治療方法,它使用多個放射束,可以客製化放射束以向腫瘤提供精確的劑量,同時最大限度地減少對周圍健康組織的暴露。替代技術的可用性是市場擴張的一個挑戰。
由於 COVID-19大流行,質子治療系統市場正在經歷重大影響。大流行期間醫療保健預算的財務壓力可能會影響投資決策並減緩質子治療系統的採用。但大流行激發了創新和適應。遠端醫療解決方案擴大用於患者諮詢和隨訪。人們越來越認知到質子治療的好處,包括減少治療相關的副作用,強調了先進癌症治療方法的重要性。
預計旋轉質子束治療系統領域將佔最大佔有率。旋轉質子治療系統利用可以圍繞患者旋轉的機架,提供從不同角度向腫瘤提供輻射的3D方法。這種動態旋轉可以更精確地靶向癌細胞,同時最大限度地減少與健康組織的接觸。此外,質子束可以從多個方向發射,這提高了其對腫瘤形狀的符合性,使其對形狀複雜且不規則的腫瘤特別有效。
預計光束傳輸系統領域在預測期內將出現良好的成長。此系統負責引導和控制來自質子加速器的高能量質子束照射到患者體內的腫瘤部位。質子束的深度和強度由能量調變、磁鐵和準直器等組件的組合來成形和調變。此外,現代光束傳輸系統通常採用掃描或點掃描技術,可逐點傳輸質子束,以實現更高的精度。
在估計期間,北美佔據了最大的市場佔有率。癌症發生率的增加以及人們對質子治療益處的認知不斷提高,正在推動這些先進系統的採用。美國著名的癌症治療中心和研究機構的存在創造了一個創新和技術採用的環境,從而促進了質子治療解決方案的開發和部署。此外,學術界、醫療機構和行業相關人員之間的合作正在促進質子治療研究的進步和最佳實踐的普及。
預計歐洲在預測期內將出現盈利成長。由於癌症發病率上升以及對創新醫療技術的日益重視,德國、英國和英國等歐洲國家對質子治療系統表現出了強勁的需求。此外,該地區還擁有領先的癌症治療中心和研究機構網路,積極致力於先進質子治療解決方案的開發和應用。
According to Stratistics MRC, the Global Proton Therapy Systems Market is growing at a CAGR of 15.6% during the forecast period. Proton therapy systems are advanced medical technologies designed for precise cancer treatment, offering enhanced therapeutic effectiveness and an improved quality of life for cancer patients. Proton therapy allows for precise dose conformity to the shape of the tumor, enabling higher radiation doses to be delivered to the cancer cells while sparing healthy tissues.
According to the WHO (World Health Organization), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
Proton therapy, as an advanced form of radiation therapy, offers several advantages in cancer treatment. It utilizes protons to precisely target tumours, delivering higher radiation doses while minimizing damage to surrounding healthy tissues. This targeted approach reduces the risk of side effects and long-term complications associated with conventional radiation therapy. Proton therapy, with its ability to provide precise and accurate radiation delivery, has gained recognition as a valuable treatment modality, which enhances market demand.
While proton therapy is an advanced and effective treatment modality, the availability and accessibility of proton therapy centers are limited compared to conventional radiation therapy facilities. The geographical distribution of proton therapy centers plays a role in limited accessibility. Moreover, patients residing in remote or rural areas may face significant challenges in accessing proton therapy due to the distance and lack of nearby facilities. Therefore, limited accessibility is a significant factor hampering market expansion.
Improved design and functionality of proton therapy machines, coupled with sophisticated treatment planning systems, enable healthcare providers to deliver highly targeted radiation doses. The integration of advanced imaging technologies enhances the accuracy of treatment delivery by providing real-time visualization of the tumor and surrounding healthy tissues. Furthermore, software innovations in treatment planning facilitate personalized and adaptive approaches, optimizing proton therapy for individual patient needs. Hence, these technological innovations accelerate market growth.
While proton therapy offers unique advantages, alternative technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) have also advanced significantly, providing comparable treatment outcomes in certain cases. IMRT, a widely adopted radiation therapy technique, uses multiple beams of radiation that can be adjusted to deliver precise doses to the tumor while minimizing exposure to surrounding healthy tissues. The availability of alternative technologies poses a challenge to market expansion.
The proton therapy systems market has experienced significant impacts from the COVID-19 pandemic. The financial strain on healthcare budgets during the pandemic has influenced investment decisions, potentially slowing down the adoption of proton therapy systems. However, the pandemic has also prompted innovation and adaptation. Telehealth solutions have been increasingly employed for patient consultations and follow-ups. Awareness of the benefits of proton therapy, such as reduced treatment-related side effects, has grown, emphasizing the importance of advanced cancer treatment modalities.
The rotating proton therapy systems segment is estimated to hold the largest share. Rotating proton therapy systems utilize a gantry that can rotate around the patient, providing a three-dimensional approach to irradiating tumours from various angles. This dynamic rotation allows for more precise targeting of cancerous cells while minimizing exposure to healthy tissues. Moreover, the ability to deliver proton beams from multiple directions enables improved conformity to the shape of the tumor, making it particularly effective for complex and irregularly shaped tumours.
The beam delivery system segment is anticipated to have lucrative growth during the forecast period. This system is responsible for directing and controlling the delivery of high-energy proton beams from the proton accelerator to the tumor site within the patient's body. The proton beam's depth and intensity are shaped and modulated by a combination of components, such as energy modulation devices, magnets, and collimators. Furthermore, modern beam delivery systems often incorporate scanning or spot-scanning techniques, allowing for even greater precision by delivering proton beams spot by spot.
North America commanded the largest market share during the extrapolated period. The increasing incidence of cancer, coupled with a growing awareness of the benefits of proton therapy, drives the adoption of these advanced systems. In the United States, the presence of renowned cancer treatment centers and research institutions fosters a climate of innovation and technology adoption, propelling the development and deployment of proton therapy solutions. Additionally, collaborations between academic institutions, healthcare organizations, and industry players contribute to research advancements and the dissemination of best practices in proton therapy.
Europe is expected to witness profitable growth over the projection period. European countries, including Germany, France, the United Kingdom, and others, exhibit a strong demand for proton therapy systems, driven by a rising incidence of cancer and an increasing emphasis on innovative medical technologies. Moreover, the region boasts a network of leading cancer treatment centers and research institutions actively engaged in the development and application of advanced proton therapy solutions.
Some of the key players in the Proton Therapy Systems Market include Mitsubishi Electric Corporation, Mevion Medical Systems, Hitachi, Advanced Oncotherapy plc, Ion Beam Applications SA, IBA worldwide, Varian, Provision Healthcare and ProTom International.
In April 2023, Mitsubishi Electric India CNC has announced partnership with SolidCAM, a global leader in innovative CAM software for CNC machines and distribution of related digital manufacturing solutions.
In August 2022, IBA, the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, announces it has signed a collaboration agreement with Apollo Hospitals Enterprise Ltd, to provide proton therapy training and education programs for IBA customers in Asia.